In the SHINE (Stroke Hyperglycemia Insulin Network Effort) trial, the patients were randomly selected to follow the therapeutic modalities of continuous intravenous insulin (intensive glucose control) or subcutaneous insulin on a sliding scale (standard glucose control) for up to 72 h. This evidence concerns the gene INS and stroke disorder.